에 대한 최신 뉴스 INVO Fertility (NASDAQ:NAYA) 주식

NAYA Biosciences

INVO Bioscience

INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body.

INVO Fertility Inc

Nayax Ltd

News

Guidance

Freeport-McMoRan Says Annual Guidance For Copper And Gold Sales Volumes Remains In Line With January 2025 Guidance

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the materials sector.
<h3 class="wp-block-heading">Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</h3>
<ul>
<li>Dividend Yield: 9.66%</li>
<li>Wells Fargo analyst Michael Sison maintained an Overweight rating and cut the price target from $40 to $35 on April 9, 2025. This analyst has an accuracy rate of 65%.</li>
<li>JP Morgan analyst Jeffrey Zekauskas downgraded the stock from Overweight to Neutral and cut the price target from $40 to $31 on April 4, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: Dow posted better-than-expected first-quarter results on Thursday.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest DOW <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0424">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0424"><img loading="lazy" decoding="async" width="913" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062048/image-148.png" alt="" class="wp-image-886183" style="width:498px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062048/image-148.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062048/image-148-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062048/image-148-768x691.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">The Chemours Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>)</h3>
<ul>
<li>Dividend Yield: 8.45%</li>
<li>Mizuho analyst John Roberts upgraded the stock from Neutral to Outperform with a price target of $19 on March 27, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Morgan Stanley analyst Vincent Andrews maintained an Equal-Weight rating and slashed the price target from $25 to $22 on Jan. 13, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: Chemours Company will issue its first quarter financial results after the closing bell on Tuesday, May 6.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest CC <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0424">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0424"><img loading="lazy" decoding="async" width="902" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062208/image-149.png" alt="" class="wp-image-886190" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062208/image-149.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062208/image-149-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062208/image-149-768x700.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Huntsman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>)</h3>
<ul>
<li>Dividend Yield: 7.75%</li>
<li>Wells Fargo analyst Michael Sison maintained an Overweight rating and cut the price target from $20 to $17 on April 9, 2025. This analyst has an accuracy rate of 65%.</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Overweight rating and cut the price target from $25 to $22 on Feb. 19, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: Huntsman will hold a conference call on Friday, May 2, to discuss its first quarter financial results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0424">HUN news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0424"><img loading="lazy" decoding="async" width="907" height="810" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062307/image-150.png" alt="" class="wp-image-886192" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062307/image-150.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062307/image-150-300x268.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24062307/image-150-768x686.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 7% Dividend Yields

Baird analyst Timothy Wojs maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Outperform and lowers the price target from $72 to $70.

Baird Maintains Outperform on Masco, Lowers Price Target to $70

Investment demonstrates confidence in America's commitment to science and innovation
Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), the world leader in serving science, will invest an additional $2 billion in the United States over the next four years, strengthening American innovation, manufacturing and economic competitiveness across the life sciences sector.
As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their medicines in America. These additional investments to the company's American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the American economy.
The $2 billion investment over the next four years includes:
<ul>
<li>$1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations</li>
<li>Complemented by $500 million in R&amp;D focused on high-impact innovation</li>
</ul>

Thermo Fisher Scientific To Invest Addl $2B to Enhance U.S. Innovation and Support Customers' Manufacturing

Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) reported quarterly earnings of $0.24 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $5.73 billion which beat the analyst consensus estimate of $5.44 billion by 5.33 percent. This is a 9.38 percent decrease over sales of $6.32 billion the same period last year.

Earnings Beats

Freeport-McMoRan Q1 Adj. EPS $0.24, Inline, Sales $5.73B Beat $5.44B Estimate

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday.
Shares of International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/25/04/44966124/ibm-shares-slide-despite-better-than-expected-q1-details">first-quarter financial results</a>.
IBM reported quarterly earnings of $1.60 per share, which beat the analyst consensus estimate of $1.40. Quarterly revenue of $14.54 billion beat the analyst consensus estimate of $14.4 billion.
IBM shares dipped 7.3% to $227.62 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) shares dipped 17.8% to $9.02 in pre-market trading after the company announced weaker-than-expected quarterly results.</li>
<li>Robert Half Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) fell 16.6% to $38.70 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Acacia Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) declined 11.1% to $2.65 in pre-market trading.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) dipped 10.3% to $4.98 in today's pre-market trading. Latham Group will release financial results for the first quarter on Tuesday, May 6, after the closing bell.</li>
<li>Kaiser Aluminum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALU#NASDAQ">KALU</a>) fell 8.2% to $54.10 in pre-market trading following weak quarterly sales.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) shares dipped 7.7% to $4.90 in pre-market trading as the company posted weaker-than-expected earnings for its first quarter and confirmed its guidance for the rest of the year.</li>
<li>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) declined 6.7% to $42.99 in pre-market trading following weaker-than-expected quarterly results.</li>
<li>Jack in the Box Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) declined 4.6% to $24.24 in pre-market trading after the company issued FY25 forecast.</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) fell 4% to $24.50 in pre-market trading as the company reported first-quarter financial results after the market close on Wednesday. Southwest Airlines pulled its full-year 2025 and 2026 EBIT guidance, citing "current macroeconomic uncertainty."</li>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) fell 3.7% to $5.76 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a> </li>
</ul>
Photo via Shutterstock

Movers

ACTG

JACK

KALU

PTON

SWIM

IBM, Nokia, Alaska Air Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Gold's sprint above $3,500 an ounce this week turned Costco's bullion aisle into a treasure hunt, with some members using credit-card perks to all but mint money out of metal.
What Happened: One first-time collector <a href="https://www.businessinsider.com/costco-gold-buyers-rewards-price-surge-2025-4">told</a> Business Insider he has poured more than $30,000 into bars and coins since January, all bought at Costco. 
"Costco was the gateway drug to gold investing," he said, admitting the speed of the rally now unnerves veteran stackers. "To me, it is the measuring stick for how bad things are going to get."
Costco lists 100-gram and 1-ounce bars online and in select warehouses. On Tuesday, the markup was so slim that Executive members paying with the Costco Citi card effectively earned 1%-2% cash back, a quirk that briefly made bullion cheaper than paper money. 
The club chain keeps no-return rules on precious metals and adjusts prices only once or twice a day, unlike live-priced bullion sites. A <a href="https://www.reddit.com/r/CostcoPM/comments/1k60w3j/market_at_the_moment/">Reddit user noted</a>, "Their pricing lags up to a day or two behind spot… which was great for customers buying when gold skyrocketed."
See also: <a href="https://www.benzinga.com/25/04/44975675/asia-markets-mixed-europe-slips-gold-gains-dollar-drops-on-policy-signals-global-markets-today-while-us-slept">Asia Markets Mixed, Europe Slips And Gold Gains On Policy Uncertainty Pressure &#8211; Global Markets Today While US Slept</a>
Costco never says how much gold it moves, but executives have called bullion a key e-commerce growth engine, with inventory batches selling out "within a few hours." A warehouse manager, who asked not to be named, told BI that his store gets 10-20 bars at a time, and they're gone in days. "The price hasn't had much of an effect. The people who want it buy it," he added.
What To Know: Gold has dazzled in 2025, leaping more than 25% year-to-date and <a href="https://www.benzinga.com/topic/gold">briefly eclipsing $3,500</a> an ounce earlier this week, as investors flock to a safe haven amid Fed-independence worries, tariff threats, and recession chatter. Yet FXTM analyst Lukman Otunuga says the metal now looks <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44929939/gold-up-30-year-to-date-but-could-be-ripe-correction-analyst">"heavily overbought,"</a> warning that technical signals point to a cooling phase. He sees a pullback toward $3,350, $3,200 or even $3,140 unless bulls can secure a daily close above $3,500 and target the next milestone at $3,600.
The surge has lifted the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) in lockstep, but a dip in bullion could hit gold-mining shares harder because of their operating leverage. Even a hawkish Federal Reserve and a resilient dollar haven't dulled bullion's allure, showing how nervous traders remain. For now, investors riding GLD's momentum may want to watch for that correction cue before assuming the rally still has room to run.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/25/04/44975884/newmont-reports-strong-q1-earnings-reaffirms-full-year-guidance">Newmont Reports Strong Q1 Earnings, Reaffirms Full-Year Guidance</a>

Commodities

Costco's Slim Markups Turned 1-Ounce Bars Into Instant Deals — And Sparked A $30,000 Shopping Spree For One Nervous Investor

WIIM

MTH stock has given up its prior loss. Meritage Homes shares were trading lower. The company reported Q1 financial results.

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) will release earnings results for the first quarter, after the closing <a href="https://www.benzinga.com/quote/GOOGL/earnings">bell on Thursday, April 24.</a>
Analysts expect the Mountain View, California-based company to report quarterly earnings at $2.01 per share, up from $1.89 per share in the year-ago period. Alphabet projects to report quarterly revenue at $89.15 billion, compared to $80.54 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Alphabet's Google is reportedly telling some remote employees to adopt a hybrid schedule or accept a voluntary exit package as part of a broader cost-cutting effort.
Alphabet shares rose 2.6% to close at $155.35 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/googl/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Mark Kelley maintained a Buy rating and cut the price target from $225 to $192 on April 23, 2025. This analyst has an accuracy rate of 80%.</li>
<li>RBC Capital analyst Brad Erickson reiterated an Outperform rating with a price target of $200 on April 23, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Morgan Stanley analyst Brian Nowak maintained an Overweight rating and cut the price target from $210 to $185 on April 17, 2025. This analyst has an accuracy rate of 68%.</li>
<li>BMO Capital analyst Brian Pitz reiterated an Outperform rating and lowered the price target from $230 to $200 on April 17, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Truist Securities analyst Youssef Squali maintained a Buy rating and decreased the price target from $220 to $200 on April 17, 2025. This analyst has an accuracy rate of 76%.</li>
</ul>
Considering buying GOOGL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24040119/image-142-1024x601.png" alt="" class="wp-image-885898" style="width:596px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24040119/image-142-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24040119/image-142-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24040119/image-142-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24040119/image-142.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a> </li>
</ul>
Photo via Shutterstock

GOOGL

Top Wall Street Forecasters Revamp Alphabet Expectations Ahead Of Q1 Earnings

Management

RRGB

Red Robin Gourmet Burgers President And CEO G.J Hart To Resign; David Pace Appointed President And CEO

VivoSim Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIVS#NASDAQ">VIVS</a>) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.
VivoSim will offer liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of the FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA's push to phase out animal models, announced on April 10, is expected to provide a powerful accelerant to VivoSim's market adoption, disrupting a &gt;$10B animal testing market with models that are more predictive and ethically sound.
As FDA Commissioner Martin A. Makary M.D., M.P.H. said in FDA's announcement: "This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use. By leveraging AI-based computational modeling, human organ model-based lab testing, and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&amp;D costs and drug prices."
VivoSim's models include physical organoid wet lab models of liver and intestine made using cells from human donors. VivoSim is developing what it believes will be industry-best in silico predictions of liver tox, intestinal tox, and permeability. Artificial intelligence (AI) models in VivoSim's NAMkind&#x2122; services suite will be trained on an extensive set of proprietary, real world data from organoid models made from human donor cells, giving much richer and more extensive information than is possible with data from human clinical trials.

Biotech

General

VIVS

Vivosim Labs Announces That It Has Emerged From Stealth Mode To Impact Drug Discovery And Development. Will Offer Liver And Intestinal Toxicology Insights Using Its New Approach Methodologies  Models

Baird analyst David Tarantino maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Outperform and lowers the price target from $62 to $56.

Baird Maintains Outperform on Chipotle Mexican Grill, Lowers Price Target to $56

Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBCP#NASDAQ">IBCP</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.70 by 5.71 percent. This is a 2.63 percent decrease over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $43.69 million which beat the analyst consensus estimate of $43.40 million by 0.66 percent. This is a 8.68 percent increase over sales of $40.20 million the same period last year.

IBCP

Independent Bank Q1 EPS $0.74 Beats $0.70 Estimate, Sales $43.69M Beat $43.40M Estimate

Guardant Health And Pfizer Collaborate On Development And Commercialization Of Cancer Therapies, Will Utilize Guardant's Portfolio Of Liquid Biopsy Tests In Pfizer's Global Clinical Studies

ASPI

ASP Isotopes Proposes Secondary Listing On Johannesburg Stock Exchange

Carpenter Technology Raises FY25 Operating Income Outlook To $520M - $527M

Southern Calif Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAL#NASDAQ">BCAL</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.40 by 30 percent. This is a 100 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $44.82 million which missed the analyst consensus estimate of $44.85 million by 0.08 percent. This is a 104.60 percent increase over sales of $21.91 million the same period last year.

Earnings Misses

BCAL

Southern Calif Bancorp Q1 EPS $0.52 Beats $0.40 Estimate, Sales $44.82M Miss $44.85M Estimate

LUCD

Lucid Diagnostics Announces Data From A National Cancer Institute Sponsored Study Demonstrating EsoGuard Can Detect Esophageal Precancer Among At-Risk Patients Without Symptoms Of GERD

SPGI

S&P Global To Acquire ORBCOMM's Automatic Identification System Business; Financial Terms Not Disclosed

Clinical results confirm biometric BLE Bluetooth chip and blockchain-based app successfully prevent underage use
Study validates next-gen approach to digital safeguards for ENDS manufacturers, setting a new standard for safety, compliance, and adult consumer control
- <a href="https://ispiretechnology.com/">Ispire Technology Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) joint venture, <a href="https://www.prnewswire.com/news-releases/ispire-berify-and-chemular-to-propel-innovation-in-vape-hardware-manufacturing-industry-302068135.html">IKE Tech LLC ("IKE Tech")</a>, a leading innovator in the intersection of Internet of Things (IoT), identity verification (IDV) and tokenization technology has announced results from a multi-center Human Factors Validation Study evaluating its Bluetooth Low Energy (BLE) System. The IKE System is the first interoperable biometric blockchain-based platform designed to control access to electronic nicotine delivery systems (ENDS).
The study assessed usability, safety, and effectiveness in preventing underage access to ENDS, using BLE-enabled chips and biometric authentication to control device access in real-time.
Results showed:
<ul>
<li>100% of users (n=101) successfully completed age verification</li>
<li>0% of underage users were able to activate a device</li>
<li>100% of devices deactivated after&nbsp;a period of inactivity or loss of Bluetooth signal</li>
<li>91% rated the app "Extremely Easy" or "Very Easy" to use</li>
<li>Errors occurred in only 1% of task attempts</li>
</ul>
"Our findings prove that digital access control is not only achievable but scalable—and essential to the future of ENDS regulation" said John Patterson, President of&nbsp;IKE Tech. "We're not just building technology. We're building a new regulatory framework, one that gives the FDA and manufacturers powerful tools to safeguard public health and ensure adult-only access. This is bigger than just a chip—it's a paradigm shift."

ISPR

IKE Tech Releases Study Demonstrating 100% Effectiveness Of First-Ever Blockchain-Based Age-Gating System For Electronic Nicotine Delivery Systems

Press Releases

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering

NAYA Biosciences Announces Nomination of New Board Members

NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment

NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed "INVO Fertility, Inc."

Comments

INVO Fertility

뉴스

에 대한 최신 뉴스 INVO Fertility (NASDAQ:NAYA) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌